Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Victory Capital Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 180,349 shares of the biopharmaceutical company’s stock after buying an additional 24,055 shares during the period. Victory Capital Management Inc. owned approximately 0.14% of Alnylam Pharmaceuticals worth $82,239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Thematics Asset Management purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $1,995,000. Mediolanum International Funds Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $11,389,000. Rakuten Investment Management Inc. purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth about $14,205,000. Generali Asset Management SPA SGR lifted its holdings in Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 3,184 shares in the last quarter. Finally, Investment Management Corp of Ontario lifted its holdings in Alnylam Pharmaceuticals by 35.4% during the 2nd quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after buying an additional 8,244 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALNY. Oppenheimer initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target for the company. Raymond James Financial reiterated an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. HC Wainwright restated a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 18th. Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Finally, Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Stock Down 2.1%

NASDAQ:ALNY opened at $320.51 on Friday. The company’s 50-day simple moving average is $353.84 and its 200-day simple moving average is $415.74. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock has a market capitalization of $42.51 billion, a P/E ratio of 187.43 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the company earned ($0.65) EPS. The company’s revenue was up 84.9% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares in the company, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 9,577 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This represents a 10.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,923 shares of company stock valued at $18,072,087 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam signed a research collaboration with Tenaya Therapeutics to identify cardiovascular genetic targets; deal includes up to $10M upfront plus up to $1.13B in milestones — expands Alnylam’s RNAi pipeline into a large new therapeutic area and creates material long‑term upside. Tenaya deal
• Positive Sentiment: Coverage highlights a Canadian reimbursement for AMVUTTRA and other reimbursement wins/trial progress that improve near‑term revenue visibility for Alnylam’s marketed RNAi drugs. These commercial developments reduce execution risk and support upside to current valuation. Canada AMVUTTRA reimbursement
• Positive Sentiment: Analyst and industry commentary notes favorable trial progress and orphan‑drug market tailwinds that underpin medium‑to‑longer term demand for Alnylam’s rare‑disease franchise. Reimbursement & trial progress
• Neutral Sentiment: Tenaya’s stock pulled back after-hours following the deal-driven rally — notable for market reaction to the collaboration but not directly material to Alnylam’s fundamentals. TNYA market reaction
• Neutral Sentiment: Short‑interest figures in recent reports show implausible “0 shares / 0 days” values — likely a reporting glitch and not a real repositioning signal for ALNY holders.
• Negative Sentiment: Clustered insider selling: CEO Yvonne Greenstreet and several EVPs disclosed multi‑thousand‑share sales (total proceeds in the low‑millions). While insiders still hold large positions, the concentrated, contemporaneous sales can create negative sentiment and short‑term downward pressure on the stock. CEO SEC filing

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.